glp-1 cardiovascular outcomes 2025 news Agonists in Diseases: Mechanisms, Clinical Evidence, and Emerging Therapies Cardiovascular Risks after GLP-1 Discontinuation

Data from the forthcoming FLOW trial are also awaited

In addition, recurrent hypoglycemia exacerbates the defective responses to subsequent hypoglycemia, thus leading to a vicious circle of reduced awareness, increased vulnerability and further episodes of hypoglycemia (Figure 13.7)

Is there a genetic test for GLP-1 response

Healthy Weight and Growth

It is important to note that the upregulation of IL-33 observed in some GLP-1 studies does not universally guarantee mucosal defense, as IL-33 can also drive potent Th2 inflammatory responses depending on the tissue context ( In 2024, Sun and colleagues investigated GLP-1 receptor agonists in a DSS-colitis model

Blevins JE, Schwartz MW, Baskin DG